Precigen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Precigen şirketinin toplam hissedar öz sermayesi $20.2M ve toplam borcu $93.5M olup, bu da borç-öz sermaye oranını 462.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $138.6M ve $118.4M dir.

Anahtar bilgiler

462.16%

Borç/özkaynak oranı

US$93.52m

Borç

Faiz karşılama oranı	n/a
Nakit	US$56.25m
Eşitlik	US$20.24m
Toplam yükümlülükler	US$118.39m
Toplam varlıklar	US$138.63m

Son finansal sağlık güncellemeleri

Analiz Makalesi • Feb 28

Recent updates

Seeking Alpha • May 21

Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)

Summary Precigen, Inc. delivered $21.6M in Q1 Papzimeos revenue, aligning with bullish expectations but leaving key launch metrics undisclosed. Management projects cash flow breakeven by year-end, but tight cash, high burn, and future margin compression raise execution risk. Papzimeos momentum is positive, yet a lack of patient-level data and potential for pent-up demand clouds true organic growth visibility. Downgrade PGEN to Hold: risk-reward has contracted, and downside risk looms if Papzimeos underdelivers relative to already-baked-in expectations. Read the full article on Seeking Alpha

Seeking Alpha • Feb 28

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

Summary BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement to advance its UltraCAR-Ts. This technology is crucial because it could change CAR-T landscape for the better. PRGN-3006 is an UltraCAR-T being developed to target patients with Acute Myeloid Leukemia; PRGN-3008 is an UltraCAR-T targeting patients with CD19 solid tumors and autoimmune disorders. Read the full article on Seeking Alpha

Seeking Alpha • Feb 10

Precigen: Successful Proof Of Platform, But Cash Worries Remain

Summary Precigen's lead asset, PRGN-2012, shows promising results in treating Recurrent Respiratory Papillomatosis, achieving a 51% complete response rate and reducing surgical interventions. Financially, Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. The company is prioritizing PRGN-2012's development, restructuring operations, and cutting 20% of its workforce to extend its cash runway. Despite financial risks, Precigen's proven platforms and promising data make it a potential worthwhile investment, pending resolution of cash issues. Read the full article on Seeking Alpha

Analiz Makalesi • Feb 28

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Jan 20

Precigen: RRP Targeting With AdenoVerse Technology Platform

Summary FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis is expected in the 2nd half of 2024. It is projected that it could earn $2 billion in peak sales globally of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. PRGN-2009 which also uses the AdenoVerse technology has one phase 2 study targeting OPSCC underway and another one targeting recurrent/metastatic cervical cancer patients expected to begin in 2024. Read the full article on Seeking Alpha

Analiz Makalesi • Nov 04

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Jul 18

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Analiz Makalesi • May 15

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

One thing we could say about the analysts on Precigen, Inc. ( NASDAQ:PGEN ) - they aren't optimistic, having just made...

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PGEN 'nin kısa vadeli varlıkları ( $101.7M ) kısa vadeli yükümlülüklerini ( $21.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: PGEN şirketinin kısa vadeli varlıkları ( $101.7M ) uzun vadeli yükümlülüklerini ( $97.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PGEN 'nin net borç/öz sermaye oranı ( 184.2% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: PGEN şirketinin borç/öz sermaye oranı son 5 yılda 99.8% seviyesinden 462.2% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: PGEN şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: PGEN tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/12 22:13
Gün Sonu Hisse Fiyatı	2026/06/12 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Precigen, Inc. 10 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ying Huang	Barclays
Derik de Bruin	BofA Global Research
Justin Walsh	B. Riley Securities, Inc.

Precigen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Precigen Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Recent updates

President recently sold US$520k worth of stock

Precigen Presents New Long-Term Durability Data for Papzimeos and Receives Seven-Year Market Exclusivity

Precigen Reports Multi-Year PAPZIMEOS Durability With FDA Exclusivity in Rare Disease Market

Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Precigen, Inc. to Report Q1, 2026 Results on May 13, 2026

Precigen, Inc., Annual General Meeting, Jun 18, 2026

Executive Chairman recently sold US$7.7m worth of stock

Consensus revenue estimates increase by 17%

New minor risk - Share price stability

Full year 2025 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Fiscal Year 2025 Results on Mar 25, 2026

Precigen, Inc. Announces the Publication for The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-And-Only Fda-Approved Therapy for RRP

Executive Chairman notifies of intention to sell stock

Independent Director recently sold US$856k worth of stock

Independent Director recently sold US$856k worth of stock

Independent Director notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Consensus EPS estimates fall by 124%, revenue upgraded

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

Precigen, Inc. to Report Q3, 2025 Results on Nov 13, 2025

Precigen, Inc. Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses After Treatment with Papzimeos

Executive Chairman recently sold US$6.2m worth of stock

New minor risk - Insider selling

Independent Director notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Precigen, Inc. announced that it expects to receive $125 million in funding

Consensus EPS estimates fall by 13%, revenue upgraded

Price target increased by 18% to US$7.25

Precigen, Inc. Announces Full FDA Approval of PAPZIMEOS (Zopapogene Imadenovec-Drba)

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 24%, EPS downgraded

President exercised options and sold US$756k worth of stock

Forecast breakeven date pushed back to 2027

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Precigen, Inc., Annual General Meeting, Jun 26, 2025

Consensus revenue estimates fall by 25%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Fiscal Year 2024 Results on Mar 19, 2025

Consensus revenue estimates increase by 42%

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

Precigen, Inc. Announces FDA Grants Priority Review to its BLA for PRGN-2012 for Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Precigen: Successful Proof Of Platform, But Cash Worries Remain

Precigen, Inc. announced that it has received $79 million in funding

New minor risk - Share price stability

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen, Inc. announced that it expects to receive $79 million in funding

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

Consensus revenue estimates fall by 12%

Price target decreased by 41% to US$6.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q2, 2024 Results on Aug 14, 2024

New minor risk - Shareholder dilution

Precigen, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

New minor risk - Share price stability

Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer

Price target increased by 11% to US$10.12

Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response

Price target increased by 11% to US$10.12

Precigen, Inc., Annual General Meeting, Jul 05, 2024

Consensus revenue estimates fall by 10%

Price target increased by 40% to US$9.12

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024

Price target decreased by 27% to US$6.50

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

President exercised options and sold US$575k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations